Intriguingly, a chemical agonist LXR-mediated the activation of ApoE secretion devastates MDSC survival by facilitating the binding of ApoE to its receptor LRP8, resulting in a fortified anti-tumor response (Tavazoie et al., 2018). Here, LRP8 is linked to neoplasm.